Byoma Acne Treatment Spot

Description

The product is identified by SPL code 34089-3. It is presented as a white to off-white, round, biconvex tablet, which is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for the treatment of acne.

There are no teratogenic effects associated with this medication. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

Healthcare professionals should ensure that the skin is thoroughly cleaned prior to the application of this product. The recommended application involves covering the entire affected area with a thin layer. This can be done one to three times daily, depending on the patient's needs and the physician's guidance.

It is advisable to initiate treatment with one application per day to minimize the risk of excessive drying of the skin. Based on the patient's response, the frequency may be gradually increased to two or three times daily as necessary or as directed by a healthcare provider.

In cases where bothersome dryness or peeling occurs, it is recommended to reduce the frequency of application to once daily or every other day to alleviate these symptoms.

Contraindications

Use is contraindicated in patients who experience skin irritation that worsens upon application. In such cases, it is advised to discontinue use and consult a healthcare professional. No other specific contraindications have been identified.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to avoid concurrent use of multiple topical acne medications, as this increases the likelihood of skin irritation and dryness. In the event that irritation occurs, it is recommended to discontinue the use of all topical acne medications and limit treatment to a single agent.

Patients should be instructed to stop use and consult a healthcare provider if skin irritation develops or worsens. Immediate medical attention is necessary if the product is ingested; patients should be directed to seek medical help or contact a Poison Control Centre without delay.

Side Effects

Patients using this product should be aware that it is intended for external use only. The most common adverse reactions reported include skin irritation and dryness, particularly when used concurrently with other topical acne medications. The likelihood of experiencing these reactions increases with simultaneous use of multiple topical agents.

In the event that skin irritation occurs or worsens, patients are advised to discontinue use and consult a healthcare professional for further guidance. It is recommended that only one topical acne medication be used at a time to minimize the risk of irritation.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of additional topical agents is recommended to allow the skin to recover. Monitoring for signs of irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of Byoma Acne Treatment Spot (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be monitored closely when using this medication. It is essential to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Centre is advised.

For topical application, it is recommended to initiate treatment with one application daily to minimize the risk of excessive skin drying. Dosage may be gradually increased to two or three times daily as needed or directed by a healthcare professional. Should patients experience bothersome dryness or peeling, the frequency of application should be reduced to once a day or every other day.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The safety of this product during pregnancy has not been established. Salicylic acid is contraindicated in pregnancy due to the potential risk to the fetus. There is a risk of teratogenic effects associated with the use of salicylic acid during this period. Therefore, pregnant women should avoid using this product unless directed by a healthcare provider. It is essential for healthcare professionals to counsel women of childbearing potential regarding these risks and to consider alternative treatments when necessary.

Lactation

There are no specific warnings or recommendations regarding the use of Byoma Acne Treatment Spot Paste in lactating mothers. Additionally, there is no information available about the potential for excretion of the product in breast milk or any associated risks to breastfed infants.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise caution and consider the overall clinical context when prescribing this medication to patients with liver problems, as the absence of specific guidance necessitates careful evaluation of potential risks and benefits.

Overdosage

In the event of an overdosage, immediate medical intervention is crucial. If the substance is ingested, healthcare professionals should advise patients or caregivers to seek medical assistance or contact a Poison Control Centre without delay.

Prompt action is essential to mitigate potential adverse effects associated with overdosage. Symptoms may vary depending on the specific substance involved; therefore, a thorough assessment by a medical professional is recommended to determine the appropriate course of action and management strategies.

Healthcare providers should ensure that patients are aware of the importance of timely reporting of any suspected overdosage to facilitate effective treatment and minimize risks.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Centre if the product is swallowed. It is important for patients to understand the potential risks associated with accidental ingestion.

Patients should be instructed to discontinue use and consult a doctor if they experience any skin irritation or if the irritation worsens. Healthcare providers should emphasize the importance of monitoring skin reactions closely.

Additionally, patients should be made aware that the likelihood of skin irritation and dryness may increase if they are using another topical acne medication concurrently. Therefore, it is recommended that patients use only one topical acne medication at a time to minimize the risk of irritation.

Storage and Handling

The product is supplied in a container designed to safeguard its integrity. It is essential to protect the product from excessive heat and direct sunlight to maintain its efficacy and safety. Proper storage conditions should be observed to ensure optimal performance.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Byoma Acne Treatment Spot, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)